Adoption of celecoxib and rofecoxib: A nationwide database study

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 2, 2005, Pages 145-152

  Helin Salmivaara, A ^a   Huupponen, R ^b   Virtanen, A ^c   Klaukka, T ^c  

^a Laakehoidon kehittamiskeskus   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Adoption; Coxibs; Non steroidal anti inflammatory drug; Patient characteristics; Physician; Prescribing

Indexed keywords

CELECOXIB; ROFECOXIB;

ARTICLE; DATA BASE; DRUG INFORMATION; DRUG USE; FINLAND; GASTROINTESTINAL HEMORRHAGE; HUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIMARY MEDICAL CARE; REHABILITATION MEDICINE; REIMBURSEMENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FINLAND; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LACTONES; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; PYRAZOLES; RETROSPECTIVE STUDIES; SEX FACTORS; SPECIALTIES, MEDICAL; SULFONAMIDES; SULFONES; TIME FACTORS;

EID: 27744485125     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00627.x     Document Type: Article

References (26)

1. Mitchell JA, Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. British Journal of Pharmacology, 128, 1121-1132.
2. National Agency for Medicines. Summary of product characteristics: URL http://spc.nam.fi/html/ hum.html [accessed 19 February 2005].
3. Day R, Morrison B, Luza A et al. (2000) A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Archives of Internal Medicine, 160, 1781-1787.
4. Deeks J, Smith L, Bradley M (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised trials. BMJ, 235, 619-623.
5. Karvonen A, Hakala M, Kankaanranta H, Kivilaakso E, Kunnamo I, Lehtola J, Martio J (2000) Safe use of nonsteroidal anti-inflammatory drugs (in Finnish). Aikakauskirja Duodecim, 116, 1914-1931.
6. NHS (2001) Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: NHS. Report no. 27. Technology appraisal guidance.
7. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A (2002) Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology, 123, 1006-1012.
8. National Agency for Medicines and Social Insurance Institution (2003) The Finnish statistics on medicines 2002. Helsinki: National Agency for Medicines and Social Insurance Institution.
9. Swedish Pharmacy Chain Apoteket. Statistics on medicines http://www.apoteket.se/apoteket/jsp/ polopoly.jsp?d=2215 [accessed 15 December 2003].
10. Läkemiddelstyrelsen. Statistics on medicines in Denmark http://www.produktresume.dk/ [accessed 15 December 2003].
11. Läkemiddelstyrelsen. Statistics on Medicines in Denmark. http://laegemiddelstyrelsen.dk/1024/vis LSArtikel.asp?artikelID=654 [accessed 19 February 2005].
12. Klaukka T (2001) The Finnish database on drug utilization. Nordic Journal of Epidemiology, 11, 19-22.
13. Rønnig M (2001) Coding and classification in drug statistics - from national to global application. Nordic Journal of Epidemiology, 11, 37-40.
14. Blowner A, Brooks A, Fenna G, Hills A, Pearce M, Morant S, Bardhan K (1997) Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Alimentary Pharmacology and Therapeutics, 11, 283-291.
15. Spiegel B, Targownik L, Dulai G, Gralnek I (2003) The cost effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals of Internal Medicine, 138, 795-806.
16. Maetzel A, Krahn M, Naglie G (2003) The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and Rheumatism, 49, 283-292.
17. Cerezo J, Hristov R, Sansuan A, Rodriguesz J (2003) Outcome trials of COX-2 selective inhibitors: global safety evaluation. European Journal of Clinical Pharmacology, 59, 169-175.
18. Helin-Salmivaara A, Klaukka T, Huupponen R (2003) Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. European Journal of Clinical Pharmacology, 59, 477-482.
19. Huupponen R, Helin-Salmivaara A, Sairanens S, Klaukka T (2001) Painkillers are used differently in Finland compared to other Nordic countries (in Finnish). Finnish Medical Journal, 56, 1904-1908.
20. National Agency for Medicines and Social Insurance Institution (2002) The Finnish statistics on medicines 2001. Helsinki: National Agency for Medicines and Social Insurance Institution.
21. Bennett K, Teeling M, Freely J (2003) "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology, 59, 645-649.
22. Harley C, Wagner S (2002) The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical Therapeutics, 25, 139-149.
23. Kerr S, Mant A, Horn F, McGeechan K, Sayer G (2003) Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Medical Journal of Australia, 179, 403-407.
24. Rogers E (1995) Diffusion of innovations. New York: The Free Press.
25. Helin A, Hoppu K, Klaukka T (1998) Problems in pharmacotherapy experienced by physicians (in Finnish). Finnish Medical Journal, 53, 4235-4240.
26. Jones MI, Greenfield SM, Bradley CP (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ, 323, 378-381.